Fall 2019 Meeting
Plenary II Disclosure Information

Charles Blanke, MD, FACP, FASCO: None
Don Dizon, MD, FACP, FASCO: None
Mark Lewis, MD: None
Olufunmilayo Olopade, MD, FACP: Co-founder and stockholder of CancerIQ; Scientific advisory board member of Tempus
Bonnie Spring, PhD: None
Plenary II Agenda

- News & Accomplishments
- Farewells and Welcomes
- Young Investigator Training Course
- SEED Award Winner
- Plenary Speakers:
  - Don Dizon, MD
  - Mark Lewis, MD
  - Bonnie Spring, PhD
  - Harry E. Hynes Memorial Lecture: Olofunmilayo Olopade, MD
News & Accomplishments
Francis S. Collins 🗣 @NIHDirector 🕛 Sep 18
New #NIH-funded study finds that ~half of phase 3 clinicaltrials by @theNCI’s SWOG Cancer Research Network were associated with advancing patient standard of care via clinical care guidelines or drug approvals.

45%
OF 182 PHASE 3 CLINICAL TRIALS
BETWEEN 1980 AND 2017
INFLUENCED GUIDELINE CARE OR NEW DRUG APPROVALS

Study quantifies impact of NIH-sponsored trials on clinical cancer
Researchers found trials add value regardless of whether findings were positive or negative.
.nih.gov

Dr. Doug Lowy 🗣 @NCIDrDougLowy 🕛 Sep 18
This study from @SWOG provides evidence for what we would expect to see: cancer clinical trials conducted in @theNCI’s National Clinical Trials Network play a critical role in identifying effective treatment options for patients.

Dr. Doug Lowy 🗣 @NCIDrDougLowy 🕛 Sep 18
This study from @SWOG provides evidence for what we would expect to see: cancer clinical trials conducted in @theNCI’s National Clinical Trials Network play a critical role in identifying effective treatment options for patients.

NCI Media Relations 🗣 @NCIMedia 🕛 Sep 18
A new study shows nearly half of phase 3 cancer clinical trials carried out by @theNCI-sponsored SWOG Cancer Research Network, one of 5 groups in NCI’s National Clinical Trials Network, were associated with clinical care guidelines or new drug approvals bit.ly/2LAgyEl

OF 182 PHASE 3 CLINICAL TRIALS
BETWEEN 1980 AND 2017
INFLUENCED GUIDELINE CARE OR NEW DRUG APPROVALS

*Industry-run $1.73 billion
Our NCI Budgets

• Good to excellent news

• NCTN, NCORP, and stats budgets all increased
NCI Funding
March 2019-2025

NCTN

<table>
<thead>
<tr>
<th>Category</th>
<th>Grant Year 5 PREVIOUS GRANT CYCLE</th>
<th>Grant Year 6 NEW GRANT CYCLE</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cost</td>
<td>$11,571,699</td>
<td>$12,139,981</td>
<td>+568,282</td>
</tr>
</tbody>
</table>

NCORP

<table>
<thead>
<tr>
<th>Category</th>
<th>Grant Year 5 PREVIOUS GRANT CYCLE</th>
<th>Grant Year 6 NEW GRANT CYCLE</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cost</td>
<td>$5,961,114</td>
<td>$6,737,472</td>
<td>+776,358</td>
</tr>
</tbody>
</table>
# NCTN Site Payments

<table>
<thead>
<tr>
<th>Accrual Type</th>
<th>Main Member/Affiliate &amp; Standard NCORP Rate</th>
<th>LAPS &amp; High-Performing NCORP Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening on Study*</td>
<td>$600 (Variable)</td>
<td>$600 (Variable)</td>
</tr>
<tr>
<td>Treatment Intervention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-IND study</td>
<td>$2,700</td>
<td>$4,300</td>
</tr>
<tr>
<td>Treatment Intervention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND study (Non-CTEP)</td>
<td>$3,000</td>
<td>$4,600</td>
</tr>
<tr>
<td>Treatment Intervention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND study (CTEP)</td>
<td>$3,600</td>
<td>$5,200</td>
</tr>
<tr>
<td>Imaging (base accrual)</td>
<td>$1,200</td>
<td>$1,200</td>
</tr>
<tr>
<td>Biospecimen Collections</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td></td>
<td>$500/pt/trial</td>
<td>$500/pt/trial</td>
</tr>
</tbody>
</table>
## NCORP Site Payments

<table>
<thead>
<tr>
<th>Accrual Type</th>
<th>Main member/Affiliate, LAPS &amp; Standard NCORP Rate</th>
<th>High-Performing NCORP Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening on Study*</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td>Cancer Control/Prevention/QOL Intervention</td>
<td>$3,000</td>
<td>$5,000</td>
</tr>
<tr>
<td>Biospecimen Collections</td>
<td>Variable</td>
<td>Variable</td>
</tr>
</tbody>
</table>
ImmunoMATCH

**NCI and the Precision Medicine Initiative®**

The Precision Medicine Initiative® (PMI) is a $2.75 million investment in the National Institutes of Health’s (NIH) fiscal year 2016 budget to accelerate biomedical research and provide clinicians with new tools to select the therapies that can be used in a more individualized approach with patients. NCI is using $1.6 million of that investment to advance the field of precision oncology. Other disease areas will be considered by NIH over the longer term.

Oncology is a natural choice as the initial focus for this ambitious initiative. Precision medicine uses the genetics of disease to identify effective therapies, and, thanks in large part to NCI-supported research, we know that cancer is a disease of the genome.

NCI has been on the forefront of precision medicine since 2014. The Institute has launched a series of precision medicine clinical trials and, as a result, many genetically targeted therapies are currently available to cancer patients.
ImmunoMATCH Details

- Master chaired by Drs. Ken Grossman and Katerina Politi
  - SWOG portfolio: Dr. Siwen Hu-Lieskovan
- Variety of eligible solid tumors
- First- and second-line therapies
- Emphasis on combinations
- Launching in 2020
SWOG Latin America Initiative

5 NCI studies close to activation

- S1802
- S1714
- S1827
- BR003
- InPACT
July 29 Plain Language Workshop
Plain Language in the NCTN

• No group currently employs a plain language writer

• Printable/shareable trial summaries posted on SWOG.org

• Our thanks to The Hope Foundation for Cancer Research
Community Advocate Program

• Brings a new “style” of advocate to SWOG

• Representation from those with a different perspective

• Helps with diversity of trial participants, including accrual tactics in special populations
Community Advocates
30 Years of Leading SWOG!
Farewells & Welcomes
Outgoing ORP Chair

Keisha Humphries, RN, BSN, OCN
Incoming ORP Chair

Connie Szczepanek, RN, BSN, CCRP
Incoming Melanoma Chair

Kenneth Grossmann, MD
Incoming Immunotherapy Co-Chair

Siwen Hu-Lieskovcan, MD, PhD
2019 Young Investigators
2019 SWOG Young Investigators

Arya Amini, MD
City of Hope

Jose Rodrigo Espinosa Fernandez, MD
Instit. Nacional de Cancerologia

Leah Ferrucci, PhD, MPH
Yale School of Public Health

Brian Hess, MD
Medical Univ. of South Carolina

Benjamin Maughan, MD, PharmD
Huntsman Cancer Institute

Jing (Christine) Ye, MD
University of Michigan
2019 SEED Award

Dan L. Hertz, PharmD, PhD
University of Michigan College of Pharmacy

Siu-Fun Wong, PharmD
Chapman University

“Prospective Drug-Drug Interaction Screening in SWOG Clinical Trials”
Plenary Speaker

Don Dizon, MD
Plenary Speaker

Mark Lewis, MD
Harry Hynes
Memorial Lecturer

Olufunmilayo Olopade, MD
מ beforeSend kedusha veiymh ador

Majgor para Rotb HaShanah ve Yom Kipur

Comunitas Jueia Beil Shalom de Catalunya

לכן,موבדו למקומם